Result description
People affected by uncontrolled epilepsy suffer from unpredictable seizures which can cause accidents, injuries and is a source of constant stress that often prohibits them from leading a normal life. The mjn-SERAS is a discrete, wearable device fitted like an earpiece which records electrical brain activity and alerts users before a seizure occurs, helping to reduce anxiety, increase patient safety, and improve their overall quality of life.
mjn-SERAS is a medical device that alerts users when the risk of epileptic seizures is high. It consists of a 3D printed earpiece that records electrical brain activity through the ear canal and a connected mobile app that sends a warning signal to the affected person and their trusted contacts minutes before a seizure is about to occur and creates reports for the patient’s doctor. Multi-centric clinical studies have demonstrated the device’s safety and efficacy in reducing epilepsy seizure-related accidents by up to 80% and improving patient quality of life by 195%. .
The mjn-SERAS solution addresses this unmet clinical need by integrating continuous EEG recording with artificial intelligence algorithms capable of estimating seizure risk in real-world conditions. Unlike hospital-based monitoring solutions, mjn-SERAS is designed as a wearable, patient-centered device to deliver individualized risk warnings, thus contributing to improved safety and quality of life for people with epilepsy”
Addressing target audiences and expressing needs
- Grants and Subsidies
- Business partners – SMEs, Entrepreneurs, Large Corporations
- Venture Capital
MJN targets different beneficiary stakeholders within the epilepsy field::
• Product customers, consumers, and end users: People with epilepsy, patients with drug-resistant epilepsy, who suffer seizures (and/or their caregivers).
• Recommenders and potential prescribers: Epilepsy specialists: neurologists, epileptologists, general practitioners, nurses; who monitor and treat patients and provide information to end users.
• Payers: Healthcare providers, public healthcare systems or private insurance companies; who buy healthcare tools to cover medical needs, taking into account savings.
- Public or private funding institutions
- Other Actors who can help us fulfil our market potential
- Private Investors
R&D, Technology and Innovation aspects
The device obtained CE marking and UKCA compliance under the new European Medical Device Regulation (EU) 2017/745. It is currently available in Spain, Germany and the UK and awaiting approval for reimbursement as a DMD, which will allow to scale through partnerships with national healthcare systems.
A distribution agreement for all Europe with Neuraxpharm, a CNS specialist pharma company, performing the reimbursement process in Germany, UK, France and Spain. An agreement with Nobelpharma in Japan for an exclusivity negotiation for local distribution. A pilot in Israel with regulatory proceedings already done, and we are working on technical specifications for Latin America and GCC regions.
Yes, we can replicate our results in Europe in other regions as Japan, USA or Latam, so we can provide the same devices, information and algorithms to all patients suffering from seizures. In all of these regions the patient is going directly to an epileptologist or a specialized neurologist, who can prescribe the solution or make the recomendation if not reimbursed
Yes, we have a business plan for next years being profitable in the second year of commercialization, but investing in new developments and better versions.
The plans are already agreed with European distributors regarding the targeted sales and profit sharing model, and other regions will be included in this business plan going forward.
- Europe
- North America
- Asia
Result submitted to Horizon Results Platform by MJN NEUROSERVEIS SL
